BioPharmaDispatch, also BPDInsights.ai, is publishing an edited version of the information provided to the unidentified participants in the second stage of the Delphi study on the definitions of 'high unmet medical need' and 'high added therapeutic value'. At least this way, those excluded can see its direction.
Now you can see the next step in the process most are officially excluded from
June 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
September 10, 2026 - - Latest News -
Which is it? The two perspectives on patient input compounded by the lack of transparency
September 10, 2026 - - Latest News
